Literature DB >> 21412787

Hepatitis B virus and sexual behavior in Rakai, Uganda.

Lara Stabinski1, Steven J Reynolds, Ponsiano Ocama, Oliver Laeyendecker, David Serwadda, Ron H Gray, Maria Wawer, David L Thomas, Thomas C Quinn, Gregory D Kirk.   

Abstract

HIV and hepatitis B virus (HBV) co-infection poses important public health considerations in resource-limited settings. Demographic data and sera from adult participants of the Rakai Health Sciences Program Cohort in Southwestern Uganda were examined to determine HBV seroprevalence patterns in this area of high HIV endemicity prior to the introduction of anti-retroviral therapy. Commercially available EIAs were used to detect prevalent HBV infection (positive for HBV core antibody [anti-HBc] and/or positive HBV surface antigen [HBsAg]), and chronic infection (positive for HBsAg). Of 438 participants, 181 (41%) had prevalent HBV infection while 21 (5%) were infected chronically. Fourteen percent of participants were infected with HIV. Fifty three percent showed evidence of prevalent HBV infection compared to 40% among participants infected with HIV (P = 0.067). Seven percent of participants infected with HIV were HBsAg positive compared to 4% among participants not infected with HIV (P = 0.403). The prevalence of prevalent HBV infection was 55% in adults aged >50 years old, and 11% in persons under 20 years. In multivariable analysis, older age, HIV status, and serologic syphilis were significantly associated with prevalent HBV infection. Transfusion status and receipt of injections were not significantly associated with HBV infection. Contrary to expectations that HBV exposure in Uganda occurred chiefly during childhood, prevalent HBV infection was found to increase with age and was associated sexually transmitted diseases (HIV and syphilis.) Therefore vaccination against HBV, particularly susceptible adults with HIV or at risk of HIV/STDs should be a priority.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412787      PMCID: PMC3262046          DOI: 10.1002/jmv.22051

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  23 in total

1.  The incidence of HIV-1 associated with injections and transfusions in a prospective cohort, Rakai, Uganda.

Authors:  Noah Kiwanuka; Ronald H Gray; David Serwadda; Xianbin Li; Nelson K Sewankambo; Godfrey Kigozi; Tom Lutalo; Fred Nalugoda; Maria J Wawer
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

2.  HBV infection in The Gambia.

Authors:  H C Whittle; K McLauchlan; A K Bradley; A B Ajdukiewicz; C R Howard; A J Zuckerman; I A McGregor
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

3.  Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda.

Authors:  E Seremba; P Ocama; C K Opio; M Kagimu; H J Yuan; N Attar; D L Thomas; W M Lee
Journal:  J Med Virol       Date:  2010-08       Impact factor: 2.327

4.  Hepatitis B virus and hiv infections among patients in Mulago hospital.

Authors:  F N Nakwagala; M M Kagimu
Journal:  East Afr Med J       Date:  2002-02

5.  Natural history and prognostic factors for chronic hepatitis type B.

Authors:  G Fattovich; L Brollo; G Giustina; F Noventa; P Pontisso; A Alberti; G Realdi; A Ruol
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

6.  The pattern of childhood hepatitis B infection in two Gambian villages.

Authors:  H Whittle; H Inskip; A K Bradley; K McLaughlan; F Shenton; W Lamb; J Eccles; B A Baker; A J Hall
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

7.  Seroepidemiological study on sexually transmitted diseases and hepatitis B in African promiscuous heterosexuals in relation to HTLV-III infection.

Authors:  P Van de Perre; N Clumeck; M Steens; G Zissis; M Caraël; R Lagasse; S De Wit; T Lafontaine; P De Mol; J P Butzler
Journal:  Eur J Epidemiol       Date:  1987-03       Impact factor: 8.082

8.  Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control.

Authors:  A Abebe; D J Nokes; A Dejene; F Enquselassie; T Messele; F T Cutts
Journal:  Epidemiol Infect       Date:  2003-08       Impact factor: 2.451

9.  Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa.

Authors:  S S Abdool Karim; R Thejpal; H M Coovadia
Journal:  Int J Epidemiol       Date:  1991-06       Impact factor: 7.196

10.  Risk factors for the spread of AIDS in rural Africa: evidence from a comparative seroepidemiological survey of AIDS, hepatitis B and syphilis in southwestern Uganda.

Authors:  C P Hudson; A J Hennis; P Kataaha; G Lloyd; A T Moore; G M Sutehall; R Whetstone; T Wreghitt; A Karpas
Journal:  AIDS       Date:  1988-08       Impact factor: 4.177

View more
  10 in total

1.  Hepatitis B incidence and prevention with antiretroviral therapy among HIV-positive individuals in Uganda.

Authors:  Emmanuel Seremba; Victor Ssempijja; Sarah Kalibbala; Ronald H Gray; Maria J Wawer; Fred Nalugoda; Corey Casper; Warren Phipps; Ponsiano Ocama; David Serwadda; David L Thomas; Steven J Reynolds
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

2.  High prevalence of hepatitis B virus infection among pregnant women attending antenatal care: a cross-sectional study in two hospitals in northern Uganda.

Authors:  Pontius Bayo; Emmanuel Ochola; Caroline Oleo; Amos Deogratius Mwaka
Journal:  BMJ Open       Date:  2014-11-11       Impact factor: 2.692

3.  Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities.

Authors:  Micah Oyaro; John Wylie; Chien-Yu Chen; Raphael O Ondondo; Anna Kramvis
Journal:  South Afr J HIV Med       Date:  2018-03-27       Impact factor: 2.744

Review 4.  Cancer Risk Studies and Priority Areas for Cancer Risk Appraisal in Uganda.

Authors:  Alfred Jatho; Binh Thang Tran; Jansen Marcos Cambia; Miisa Nanyingi; Noleb Mugume Mugisha
Journal:  Ann Glob Health       Date:  2020-07-07       Impact factor: 2.462

5.  Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.

Authors:  Lucy Platt; Clare E French; Catherine R McGowan; Keith Sabin; Erin Gower; Adam Trickey; Bethan McDonald; Jason Ong; Jack Stone; Philippa Easterbrook; Peter Vickerman
Journal:  J Viral Hepat       Date:  2019-12-22       Impact factor: 3.728

6.  Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia.

Authors:  Michael J Vinikoor; Edford Sinkala; Annie Kanunga; Mutinta Muchimba; Arianna Zanolini; Michael Saag; Jake Pry; Bright Nsokolo; Tina Chisenga; Paul Kelly
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

7.  A Serological Survey of Selected Papua New Guinea Blood Donors for Hepatitis B and Related Co-Infections.

Authors:  Francisca Varpit; Bruce Gummow
Journal:  Trop Med Infect Dis       Date:  2020-06-29

8.  Hepatitis B virus infection and factors associated with its acquisition among adults in a Lake Victoria HIV hyperendemic fishing community in Kyotera district, Uganda: a cross-sectional observation.

Authors:  Charles Ssuuna; Victor Ssempijja; Sarah Kalibbala; David Serwadda; Ping Teresa Yeh; Maria Wawer; Ronald Gray; Larry Chang; Joseph Kagaayi; Steven Reynolds
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

9.  Hepatitis B prevalence and incidence in the fishing communities of Lake Victoria, Uganda: a retrospective cohort study.

Authors:  Paul Kato Kitandwe; Enoch Muyanja; Teddy Nakaweesa; Annet Nanvubya; Ali Ssetaala; Juliet Mpendo; Brenda Okech; Bernard S Bagaya; Noah Kiwanuka; Matt A Price
Journal:  BMC Public Health       Date:  2021-02-23       Impact factor: 3.295

10.  High burden of hepatitis B infection in Northern Uganda: results of a population-based survey.

Authors:  Emmanuel Ochola; Ponsiano Ocama; Christopher G Orach; Ziadah K Nankinga; Joan N Kalyango; Willi McFarland; Charles Karamagi
Journal:  BMC Public Health       Date:  2013-08-07       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.